Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited in competition
WADA 2026: S6.B, specified, prohibited in competition. The future 2027 List retains this classification. [1] [2]
2026 and 2027 List, S6.B, printed pp.15–16; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical use and evidence limits
The US midodrine label concerns disabling symptomatic orthostatic hypotension. Its active metabolite acts at alpha-1 receptors. The indication relies primarily on increased standing systolic blood pressure, a surrogate; the reviewed label says improved daily-living ability had not been verified. [3]
- A blood-pressure endpoint is not proof of broad functional improvement or benefit to healthy athletes.
Health concerns
Marked high blood pressure while lying down is the major boxed-warning concern. A therapeutic indication does not remove S6.B status. [3]
- Individual risk and treatment decisions require clinical assessment.
What remains uncertain
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S6 pp.15–16
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S6 pp.15–16
- M21. DailyMed. Midodrine hydrochloride label, supine-hypertension warning. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Boxed warning · Indications; clinical pharmacology; boxed warning
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.